Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | HUANG, Ru Chih C. | en_US |
dc.contributor.author | MOLD, David | en_US |
dc.contributor.author | JACKSON, Tiffany | en_US |
dc.contributor.author | LIN, Yu-Ling | en_US |
dc.contributor.author | LIAO, Kuang-Wen | en_US |
dc.date.accessioned | 2019-04-11T06:20:45Z | - |
dc.date.available | 2019-04-11T06:20:45Z | - |
dc.date.issued | 2017-10-05 | en_US |
dc.identifier.govdoc | A61K031/435 | en_US |
dc.identifier.govdoc | A61P035/00 | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/151540 | - |
dc.description.abstract | In accordance with the present invention, the immunoregulatory activity of low doses of P4N was investigated. Unlike previously described antitumor drugs, low dose P4N, in doses of about 1 to 10 mg/kg, or at concentrations of about 10 to 100 nM, was surprisingly found to contribute to humoral immunity by raising the titers and activities of autoantibodies against GRP78 and F1F0 ATP synthase on the surface of CT26 cells, and inducing B cell proliferation and differentiation of plasma cells. Methods for inducing endogenous antitumor autoantibodies (EAA) in a subject having a neoplasia comprising administering to the subject an effective amount of the nordihydroguaiaretic acid (NDGA) derivative P4N, or salts, solvates and stereoisomers thereof, as well as methods for inducing B cell proliferation, inducing BAFF stimulated B cell proliferation, and suppressing or inhibition growth of a neoplasia are also provided. | en_US |
dc.language.iso | en_US | en_US |
dc.title | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | en_US |
dc.type | Patents | en_US |
dc.citation.patentcountry | WSA | en_US |
dc.citation.patentnumber | WO2017173022 | en_US |
Appears in Collections: | Patents |
Files in This Item:
If it is a zip file, please download the file and unzip it, then open index.html in a browser to view the full text content.